Which medications in the drug class Phosphodiesterase (type 5) Enzyme Inhibitor are used in the treatment of Pediatric Mixed Connective Tissue Disease?

Updated: Oct 24, 2018
  • Author: Marisa S Klein-Gitelman, MD, MPH; Chief Editor: Lawrence K Jung, MD  more...
  • Print

Phosphodiesterase (type 5) Enzyme Inhibitor

These agents increase peripheral vasodilation and may be helpful in treating symptoms associated with Raynaud disease.

Sildenafil (Revatio)

Inhibits phosphodiesterase type 5 in smooth muscle of pulmonary vasculature in which phosphodiesterase type 5 is responsible for the degradation of cGMP. Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur. The systemic vasodilation may be helpful to reduce Raynaud disease symptoms.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!